

Title (en)

USE OF CANNABINOIDS IN THE TREATMENT OF OCULAR INFLAMMATION AND/OR PAIN

Title (de)

VERWENDUNG VON CANNABINOÏDEN ZUR BEHANDLUNG VON AUGENENTZÜNDUNGEN UND/ODER SCHMERZEN

Title (fr)

UTILISATION DE CANNABINOÏDES DANS LE TRAITEMENT DE L'INFLAMMATION ET/OU DE LA DOULEUR OCULAIRE

Publication

**EP 3302464 A4 20190123 (EN)**

Application

**EP 16799004 A 20160527**

Priority

- US 201514722991 A 20150527
- CA 2016050603 W 20160527

Abstract (en)

[origin: WO2016187722A1] Ocular compositions comprising a CB2 target agent and a cannabimimetic agent that is a non-selective cannabinoid receptor agent are useful in the treatment of ocular inflammation and ocular neuropathic pain. The CB2 target agent may be a CB2 agonist, a CB2 partial agonist, or a CB2 positive allosteric modulator. In preferred embodiments, the CB2 target agent is dimethyl heptyl cannabidiol (CBD-DMH), while the cannabimimetic agent is selected from the group consisting of Δ8-tetrahydrocannabinol (Δ8-THC), Δ9-tetrahydrocannabinol, (Δ9-THC), CP55940, and WIN55212-2.

IPC 8 full level

**A61K 31/352** (2006.01); **A61K 31/05** (2006.01); **A61K 45/06** (2006.01); **A61P 25/02** (2006.01); **A61P 27/02** (2006.01); **A61P 29/00** (2006.01); **C07C 39/23** (2006.01); **C07D 311/80** (2006.01)

CPC (source: EP)

**A61K 31/05** (2013.01); **A61K 31/352** (2013.01); **A61K 45/06** (2013.01); **A61P 25/02** (2017.12); **A61P 29/00** (2017.12)

Citation (search report)

- [XPI] WO 2015074137 A1 20150528 - LYNCH MARY [CA], et al
- [XI] WO 2014100231 A1 20140626 - KOTZKER CONSULTING LLC [US]
- [I] US 2009247619 A1 20091001 - STINCHCOMB AUDRA L [US], et al
- See references of WO 2016187722A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

**WO 2016187722 A1 20161201**; EP 3302464 A1 20180411; EP 3302464 A4 20190123

DOCDB simple family (application)

**CA 2016050603 W 20160527**; EP 16799004 A 20160527